124 related articles for article (PubMed ID: 20933513)
1. Comparison of two different radioimmunoassays to measure 17-hydroxyprogesterone during treatment monitoring of children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Kamrath C; Böhles H; Maser-Gluth C
Clin Chim Acta; 2011 Jan; 412(1-2):186-9. PubMed ID: 20933513
[TBL] [Abstract][Full Text] [Related]
2. Limited value of serum steroid measurements in identification of mild form of 21-hydroxylase deficiency.
Török D; Halász Z; Garami M; Homoki J; Fekete G; Sólyom J
Exp Clin Endocrinol Diabetes; 2003 Feb; 111(1):27-32. PubMed ID: 12605347
[TBL] [Abstract][Full Text] [Related]
3. Urinary 17 alpha-hydroxyprogesterone in management of 21-hydroxylase deficiency.
Lim YJ; Yong AB; Warne GL; Montalto J
J Paediatr Child Health; 1995 Feb; 31(1):47-50. PubMed ID: 7748691
[TBL] [Abstract][Full Text] [Related]
4. [Determination of serum steroids in monitoring therapy of congenital adrenal hyperplasia].
Xiao HW; Ma HM; Su Z; Du ML; Li YH; Chen HS; Chen QL
Zhonghua Er Ke Za Zhi; 2012 Apr; 50(4):301-7. PubMed ID: 22801236
[TBL] [Abstract][Full Text] [Related]
5. [Neonatal mass-screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. I. Microfilter paper methods for radioimmunoassay of 17 alpha-hydroxyprogesterone].
Shimozawa K
Nihon Naibunpi Gakkai Zasshi; 1983 Dec; 59(12):1845-9. PubMed ID: 6609091
[TBL] [Abstract][Full Text] [Related]
6. Reversed-phase high-performance liquid chromatography separation of adrenal steroids prior to radioimmunoassay: application in congenital adrenal hyperplasia.
Fernandes VT; Ribeiro-Neto LM; Lima SB; Vieira JG; Verreschi IT; Kater CE
J Chromatogr Sci; 2003; 41(5):251-4. PubMed ID: 12841953
[TBL] [Abstract][Full Text] [Related]
7. [Determination of urinary 17 alpha-hydroxyprogesterone excretion using ELISA--evaluation of normal subjects and patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
Shibata Y
Nihon Naibunpi Gakkai Zasshi; 1991 Aug; 67(8):819-39. PubMed ID: 1813324
[TBL] [Abstract][Full Text] [Related]
8. [Identification of congenital adrenal hyperplasia by measurement of blood-spot 17-hydroxyprogesterone].
Sólyom J; Eckhardt G; Török D
Orv Hetil; 2004 Oct; 145(40):2051-6. PubMed ID: 15559532
[TBL] [Abstract][Full Text] [Related]
9. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.
Fingerhut R
Steroids; 2009 Aug; 74(8):662-5. PubMed ID: 19463687
[TBL] [Abstract][Full Text] [Related]
10. [Salivary 17-hydroxyprogesterone concentration in monitoring of the treatment of congenital adrenal hyperplasia].
Arisaka O; Shimura N; Nakayama Y; Arisaka M; Yabuta K
Dtsch Med Wochenschr; 1988 Dec; 113(49):1913-5. PubMed ID: 3197614
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunoassay of blood-spot 17 alpha-hydroxyprogesterone in the management of congenital adrenal hyperplasia.
Robinson JA; Dyas J; Hughes IA; Riad-Fahmy D
Ann Clin Biochem; 1987 Jan; 24 ( Pt 1)():58-65. PubMed ID: 3827186
[TBL] [Abstract][Full Text] [Related]
12. Usefulness and limitations of an in-house direct radioimmunoassay for 17-hydroxyprogesterone in serum.
Lo MS; Ng ML; Wu LL; Azmy BS; Khalid BA
Malays J Pathol; 1996 Jun; 18(1):43-52. PubMed ID: 10879224
[TBL] [Abstract][Full Text] [Related]
13. Augmented 17 alpha-hydroxyprogesterone response to ACTH stimulation as evidence of decreased 21-hydroxylase activity in patients with incidentally discovered adrenal tumours ('incidentalomas').
Seppel T; Schlaghecke R
Clin Endocrinol (Oxf); 1994 Oct; 41(4):445-51. PubMed ID: 7955456
[TBL] [Abstract][Full Text] [Related]
14. Salivary and plasma androstenedione and 17-hydroxyprogesterone levels in congenital adrenal hyperplasia.
Otten BJ; Wellen JJ; Rijken JC; Stoelinga GB; Benraad TJ
J Clin Endocrinol Metab; 1983 Dec; 57(6):1150-4. PubMed ID: 6605355
[TBL] [Abstract][Full Text] [Related]
15. Scalp hair 17-hydroxyprogesterone and androstenedione as a long-term therapy monitoring tool in congenital adrenal hyperplasia.
Noppe G; de Rijke YB; Koper JW; van Rossum EF; van den Akker EL
Clin Endocrinol (Oxf); 2016 Oct; 85(4):522-7. PubMed ID: 27061431
[TBL] [Abstract][Full Text] [Related]
16. Monitoring congenital adrenal hyperplasia using blood spot 17-hydroxyprogesterone assay.
Santos CM; Abad LR; Cua SC; Domingo CF
Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():174-8. PubMed ID: 15906729
[TBL] [Abstract][Full Text] [Related]
17. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia.
Cavarzere P; Samara-Boustani D; Flechtner I; Dechaux M; Elie C; Tardy V; Morel Y; Polak M
Eur J Endocrinol; 2009 Aug; 161(2):285-92. PubMed ID: 19451212
[TBL] [Abstract][Full Text] [Related]
18. Prenatal diagnosis of 21-hydroxylase deficiency congenital adrenal hyperplasia by simultaneous radioimmunoassay of 21-deoxycortisol and 17-hydroxyprogesterone in amniotic fluid.
Gueux B; Fiet J; Couillin P; Raux-Demay MC; Mornet E; Galons H; Villette JM; Boue J; Dreux C
J Clin Endocrinol Metab; 1988 Mar; 66(3):534-7. PubMed ID: 3258316
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma 21-deoxycorticosterone (21-DB) levels in late-onset adrenal 21-hydroxylase deficiency suggest a mild defect of the mineralocorticoid pathway.
Fiet J; Gueux B; Raux-DeMay MC; Kuttenn F; Vexiau P; Brerault JL; Couillin P; Galons H; Villette JM; Julien R
J Clin Endocrinol Metab; 1989 Mar; 68(3):542-7. PubMed ID: 2537337
[TBL] [Abstract][Full Text] [Related]
20. Monitoring steroid replacement therapy in children with congenital adrenal hyperplasia.
Birkebaek NH; Hougaard DM; Cohen AS
J Pediatr Endocrinol Metab; 2017 Jan; 30(1):85-88. PubMed ID: 27977405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
